State Institute for Drug Control

Report No: ***sukls245726/2019***

STATEMENT OF NON-COMPLIANCE WITH GMP

Exchange of information between National Competent Authorities (NCAs) of the EEA following the discovery of serious GMP non-compliance at a manufacturer[1]

Part 1

Issued following an inspection in accordance with
Art. 111(7) of Directive 2001/83/EC as amended

The competent authority of Czechia confirms the following:
The manufacturer: ***VAKOS XT a.s.***
Site address: ***Pernerova 32/10, Praha 8, 186 00, Czech Republic***

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on ***2019-11-05***, it is considered that **it does not comply with the Good Manufacturing Practice** requirements referred to in

- The principles and guidelines of Good Manufacturing Practice laid down in Directive 2003/94/EC

Note to receiving authorities: Please contact the issuing authority within 20 working days in case there are critical(2) medicinal products potentially affected by this statement.
Manufacturing Authorisation Holders directly affected by this statement have failed to comply with their obligations under Art. 46 of Directive 2001/83/EC or Art. 93(1)(j) to (l) of Regulation (EU) 2019/6 and as a consequence the Qualified Person referred to in Art. 48 of Directive 2001/83/EC and Art. 97(1) of Regulation (EU) 2019/6 is unable to perform the batch certification referred to in Art. 51 of Directive 2001/83/EC and Art. 97 (6) and (7) of Regulation (EU) 2019/6.
In exceptional circumstances there may be no objection to the Qualified Person certifying affected batches thereby allowing their release provided all of the following conditions are fulfilled:

1. Batch certification is performed in order to maintain supply of critical medicinal products only.
2. A documented risk assessment has been performed by, or on behalf of, the Qualified Person and additional actions have been implemented by the manufacturing and/or batch release site to mitigate the risks posed by the non-compliance. Note: Repeated testing alone is not normally sufficient risk mitigation but, together with other actions, can form part of a strategy commensurate with the nature and the level of risk.
3. A thorough risk-benefit evaluation has been performed for the acceptance of risk and a report prepared that takes full account of the nature of the non-compliance with the involvement of:
    - The Manufacturing Authorisation Holder and the Qualified Person of the site responsible for batch certification.
    - The manufacturing site subject to this Statement of Non-Compliance, if different from the above.
    - The relevant Marketing Authorisation Holder(s).

The report has been shared with the National Competent Authorities of the countries in which distribution of

the affected batches is anticipated and that any comments from those authorities have been taken into account.

4. Written confirmation has been obtained from the National Competent Authorities in whose territories the affected batches are intended to be distributed that the product is considered critical on its territory, and that there is no objection to distribution.
5. The Supervisory Authority has been informed, if different from the above, and it has not suspended or revoked the relevant Manufacturing Authorisation.
6. The affected Marketing Authorisations have not been revoked or suspended.
7. Any further conditions imposed by the Supervisory Authority and other involved National Competent Authorities are met.

---

[1] *The statement of non-compliance referred to in paragraph 111(7) of Directive 2001/83/EC and Art. 94(2) of Regulation (EU) 2019/6, as amended, is also applicable to importers.*

[2] *See Appendix 3 of the relevant procedure in the Compilation of Union Procedures.*

Part 2

Human Medicinal Products

1 NON-COMPLIANT MANUFACTURING OPERATIONS	
Include total and partial manufacturing (including various processes of dividing up, packaging or presentation), batch release and certification, storage and distribution of specified dosage forms unless informed to the contrary;	
1.2	**Non-sterile products**
	1.2.1 Non-sterile products (processing operations for the following dosage forms) 1.2.1.5 Liquids for external use 1.2.1.6 Liquids for internal use 1.2.1.17 Other: vaginal globules(en)
	1.2.2 Batch certification
1.4	**Other products or manufacturing activity**
	1.4.1 Manufacture of 1.4.1.2 Homoeopathic products
1.5	**Packaging**
	1.5.1 Primary Packaging 1.5.1.5 Liquids for external use 1.5.1.6 Liquids for internal use 1.5.1.17 Other non-sterile medicinal products: vaginal globules(en)
	1.5.2 Secondary packaging
1.6	**Quality control testing**
	1.6.3 Chemical/Physical

Part 3

1.Nature of non-compliance:
Totally 25 deficiencies were found, 1 was classified as critical, 17 as major. The critical deficiency was related to premises: A mould was found on several places in the washing room. 2 major deficiencies were found in the Quality Management - system of deviations and change control was not established. 16 major deficiencies cover requirements on premises and equipment, e.g. production a storage rooms are not cleaned properly, dead insects were found in light covers in production rooms, walls and ceilings do not allow a proper cleaning. HVAC system is not set properly, a pressure drop leads from the room with the highest risk of contamination to production rooms. Microbiological monitoring is insufficient. Computerized systems in QC are not controlled. Cleaning validation was performed only formally.
Action taken/proposed by the NCA **Suspensionof the manufacturing authorisation No. sukls78312/2017in Full** This manufacturer should not be authorized in any new/ongoing marketing authorization or variation application. **Withdrawal, of current valid GMP certificate No. sukls426470/2018** GMP certificates invalidated

Suspensionof the marketing authorisation(s)
This manufacturer should not be authorized in any new/ongoing marketing authorization or variation application.

Recall of batches already released
A recall of medicinal products should be evaluated by involved NCAs following the assessment.

2019-11-22

Name and signature of the authorised person of the Competent Authority of Czechia

---

Confidential
State Institute for Drug Control
Tel:***Confidential***
Fax:***Confidential***